96. Crohn disease Clinical trials / Disease details
Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01881464 (ClinicalTrials.gov) | May 2014 | 11/6/2013 | Anti TNF a Improves Endothelial Dysfunction in IBD Patients | Anti TNF a Improves Endothelial Dysfunction in IBD Patients | Crohn's Disease | Device: Endopath from Itamar medical - FDA approved device.;Drug: Anti TNF Alfa. | Carmel Medical Center | NULL | Recruiting | 18 Years | 40 Years | Both | 20 | Israel |